Business Information
The group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. The group markets human therapeutic products in the areas of hematology, oncology, and inflammation. The group's key products include epogen(R), aranesp(R), neulasta(R), neupogen(R), enbrel(r). Epogen(R) and aranesp(R) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and neupogen(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. Enbrel(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis. The group's other products include kineret(R) and stemgen(r). It maintains a sales and marketing force in the United States, Europe, Canada, Australia, and New Zealand.
|
|
Name |
Title
|
Email
|
| Kevin Sharer | Chmn., CEO, Pres. | N/A | | Robert Bradway | CFO, Exec. VP | N/A | | Brian McNamee | Sr. VP - Human Resources | N/A | | Fabrizio Bonanni | Exec. VP - Operations | N/A | | George Morrow | Exec. VP - Global Commercial Operations | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 14,268,000 | 2,950,000 | | 2005 | 12,430,000 | 3,674,000 | | 2004 | 10,550,000 | 2,363,000
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
